Articles tagged with Melanoma
A new study maps out the genetic changes in melanoma development, confirming sun exposure's role and identifying an intermediate disease stage between benign moles and malignancy. The research provides evidence of UV-induced mutations in benign lesions, precursor lesions, and melanoma, highlighting the importance of sun protection.
Researchers at King's College London have identified a method to quickly estimate total body mole count using a smaller 'proxy' area, like the arm. Females with over 7 moles on their right arm had 9 times more risk of having 50+ moles overall, while those with 11 or more had 100+, indicating higher melanoma risk.
A new study shows that surgical removal of abdominal metastases can significantly improve overall survival for patients with stage IV melanoma. In this comprehensive study of over 1,600 patients, surgeons found that surgical resection provided a median survival time of 18 months compared to seven months for nonsurgical patients.
A study found that training patients with melanoma and their partners on skin examinations increased patient self-efficacy in performing self-examinations. The intervention showed the greatest benefit for pairs with low relationship quality and limited time together.
A combination of dabrafenib and trametinib significantly prolongs median overall survival time for advanced melanoma patients to over two years, with 51% remaining alive after two years. The treatment also improves disease-free progression and quality of life compared to vemurafenib alone.
Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
A new report by Eliezer Van Allen and colleagues found that melanoma patients who benefit from ipilimumab immunotherapy have unique tumor-produced antigens. The study suggests that predicting which patients will respond to the treatment may be challenging due to differences in molecular targets.
Organ transplant recipients are more susceptible to developing regional stage melanoma due to immunosuppressive medications. The study found that transplant patients were four times more likely to be diagnosed with regional stage melanoma and three times more likely to die from the disease.
Researchers at UC Davis found that a novel combination therapy of Interleukin (IL)-2 combined with imiquimod and topical retinoid is highly effective in treating patients with skin metastases, resulting in complete clinical response and high survival rates.
The University of Kentucky's Dr. John D'Orazio is leading a 3-year research project on melanoma, the deadliest form of skin cancer, with a focus on hormonal pathways and DNA repair. The study aims to understand how specific hormones affect melanocortin1 receptor signaling, which is linked to an increased risk of developing melanoma.
Scientists have uncovered five new common genetic risk factors for melanoma and confirmed two others, establishing the role of telomeres in its development. Skin pigmentation is also a key genetic determinant, emphasizing the importance of sun protection for individuals with pale skin and many moles.
A Yale study identified NF1 as a key gene in melanoma development and progression. The research revealed that 45% of melanomas without known BRAF or NRAS mutations display loss of NF1 function, leading to cancer-causing pathways.
Researchers Neil Ganem and Anurag Singh at Boston University School of Medicine are developing new strategies to inhibit the growth of chromosomally unstable cancer cells expressing oncogenic BRAF. They have identified two major types of NRAS networks in melanoma, which may be targeted with selective anti-cancer agents.
A large analysis suggests frequent citrus fruit and juice consumption may increase melanoma risk by 36% in people who eat them daily. The association is strongest for grapefruit, but not processed juices.
Researchers from Umea University found no association between PDEi drugs and increased melanoma risk; instead, men taking these drugs are more health-conscious and sunbathe more often, increasing their melanoma diagnosis risk.
A study found that use of phosphodiesterase type 5 inhibitors for erectile dysfunction was associated with a modest but significant increased risk of malignant melanoma in Swedish men. The most pronounced increase in risk was observed in men who had filled a single prescription, but not among those with multiple prescriptions.
Google searches for information on melanoma and skin cancer rose over summer months from 2010 to 2014. The correlation between these searches and actual melanoma incidence and mortality rates was limited, suggesting that increased search volumes do not necessarily translate to improved detection rates.
Clinical trials demonstrate improved survival rates for patients with metastatic melanoma using immune therapies nivolumab and pembrolizumab. These treatments target the 'don't attack' protein PDL1 on tumors, allowing the immune system to prime against tumor tissue.
Researchers found that combining immunotherapy drugs nivolumab and ipilimumab significantly increases progression-free survival in advanced melanoma patients, with a median PFS of 11.5 months compared to 6.9 months for nivolumab alone.
Nivolumab has shown promise as a therapeutic agent for improving survival rates in melanoma patients. The most common adverse events were fatigue, pruritus, diarrhea, and rash, which were primarily low-grade and manageable with immunomodulatory agents.
Researchers found traditional teaching methods focus on factual knowledge rather than visual training, leading to improved results with perceptual training modules. Undergraduate students reached expertise in identifying skin cancers and benign lesions within two hours of training.
Researchers from NYU Langone present 30 abstracts on various cancer types, including immunotherapy studies for melanoma and pediatric leukemia. Key findings highlight the potential for personalized medicine and improved outcomes in cancer patients.
A phase 3 international trial found that ipilimumab improved recurrence-free survival in advanced stage melanoma patients who underwent surgical resection. The study showed that patients with microscopic metastatic disease responded best to ipilimumab treatment.
Researchers found hundreds of possible new genes that could transform benign skin growths into deadly melanomas when combined with the Braf V600E mutation. The discovery provides new targets for slowing or stopping cancer growth.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
Researchers have linked a new protein, megalin, to aggressive malignant melanoma cells that are more likely to spread. The protein's presence can improve cancer cell division and survival, making it a potential marker for early detection and targeted treatment options.
A multicenter clinical trial launched by Yale University aims to evaluate the effectiveness of personalized medicine in treating metastatic melanoma. The trial will enroll patients lacking a particular genetic mutation and use molecular sequencing techniques to match targeted drugs to unique genetic alterations.
Researchers found a decrease in pediatric melanoma cases in the US from 2000-2010, with an overall decline of 12% per year. The number of new cases decreased in boys and adolescents, particularly those with good prognostic indicators.
A study of 32,501 melanoma cases found that 1 in 5 patients experienced a delay of surgery lasting longer than 1.5 months. Surgical delays were more common among older patients and those with prior melanoma or multiple medical conditions.
A Yale study found that one in five Medicare patients with melanoma experience significant delays in getting surgery, affecting their psychological well-being and healthcare quality. The study analyzed data from over 32,000 Medicare patients and revealed that 22% waited longer than 1.5 months for treatment.
Researchers found that Nodal protein promotes melanoma cell growth and survival, leading to improved treatment outcomes with anti-Nodal antibody combinations. The study provides hope for patients with metastatic melanoma, a disease with limited treatment options.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.
A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
Experts suggest that targeted screening programs for middle-aged and older patients using newer diagnostic tools could significantly reduce melanoma mortality rates. Studies in Australia and Germany have shown a substantial decrease in melanoma-related deaths after implementing comprehensive skin cancer screening programs.
Epidemiological and pre-clinical studies suggest coffee has a protective effect against non-melanoma skin cancers, but the link to cutaneous melanoma is less clear. A study found that high coffee intake was inversely associated with a 20% lower risk of malignant melanoma, especially in caffeinated coffee drinkers.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
The Myriad myPath Melanoma test has been shown to improve patient care through more definitive diagnoses of skin lesions, particularly in difficult-to-call cases. This resulted in a 49% change in physicians' treatment recommendations for patients with melanoma subtypes.
A phase 2 clinical trial found that adding sargramostim to ipilimumab improved overall survival in patients with metastatic melanoma. The combination treatment also had lower toxicity compared to ipilimumab alone.
A phase 2 clinical trial found that combining ipilimumab with sargramostim improved overall survival by nearly five months and reduced serious side effects. The treatment combination also showed a higher one-year survival rate of 68.9% compared to 52.9% in the ipilimumab-only group.
Researchers found melanoma cells create their own 'green light' signal using lysophosphatidic acid (LPA) to spread quickly and aggressively. This 'breadcrumb trail' allows cancer cells to travel rapidly around the body, making treatment challenging.
Researchers analyzed cultural and historical forces to estimate historic changes in UV exposure contributing to the rise in melanoma cases. Changes in fashion and clothing design, as well as increased leisure time and sun exposure, are identified as key factors.
A phase 3 trial found that combining dabrafenib with trametinib significantly reduces disease progression and death risk in metastatic melanoma patients. The therapy results in a 67% complete or partial response rate compared to 51% on monotherapy.
Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
Combination therapy with vemurafenib and cobimetinib achieves greater progression-free survival and response rates than vemurafenib alone in BRAF-mutation positive melanoma. The study also shows a reduced incidence of skin-related side-effects with combination therapy.
The European Organisation for Research and Treatment of Cancer (EORTC) will showcase its latest cancer research findings at the ESMO 2014 Congress. The conference will feature various sessions, including a joint symposium on clinical trials and posters focused on immunotherapy and gastrointestinal tumors.
A recent study published in the Journal of the National Cancer Institute has established a link between longer telomeres and increased melanoma risk. The research team identified seven genetic variations associated with telomere length and found that those with the longest telomeres are at a 30% increased risk of developing melanoma.
A new study from the University of Leeds has uncovered a genetic risk factor for melanoma, with longer telomeres associated with a higher risk. The research found that individuals with shorter telomeres are at a 30% increased risk of developing melanoma.
The Wistar Institute and Penn Medicine have collaborated on a $12.1 million SPORE grant to develop new therapies for melanoma. The goal of this project is to translate fundamental laboratory discoveries into new therapeutics that will benefit patients with melanoma and other skin cancers.
A retrospective study found that 62% of veterans reported getting sunburned while deployed, and 29% noticed changes in their moles, highlighting a potential deficiency in sun protection among military personnel. The study suggests room for improvement in skin cancer prevention and early detection in the military population.
The myPath Melanoma test differentiates malignant melanoma from benign skin lesions with over 90% accuracy, reducing indeterminate diagnoses by 76%. This improved diagnostic tool also changed treatment recommendations in 35% of cases, supporting its integration into clinical practice.
A systematic review and meta-analysis of 19 studies found that airline pilots and cabin crews have a higher incidence of melanoma, with a combined standardized incidence ratio of 2.21 for any flight-based occupation. This increased risk is attributed to exposure to UV radiation during flights.
A study found that high-mitotic rate melanomas are more likely to occur on the head and neck, grow rapidly, and be present in older men with a history of solar keratosis. These tumors have distinct clinical features, including nodular structure and amelanosis, which may pose a challenge to timely detection.
Acral melanomas, which affect the hands and feet, have unique DNA damage patterns not caused by UV radiation. Researchers sequenced tumor samples and found distinct genetic faults driving this rare skin cancer. Understanding these faults may lead to better treatments for acral melanoma.
Researchers have developed a new hand-held device that uses photoacoustic microscopy to accurately measure the depth of melanoma tumors in living tissue. This technology has the potential to improve diagnosis, prognosis, and treatment planning for melanoma patients by providing valuable information on tumor volume.
A new UK study reveals that a genetic defect in the melanocortin1 receptor (MC1R) may make people more susceptible to developing melanoma. The study found that MC1R defects contribute to melanoma development by delaying DNA repair and increasing cancerous mutations.
Research conducted at Texas Biomedical Research Institute found that sunscreen use in infancy and childhood reduces malignant melanoma incidence in adulthood by 10-fold. The study used a natural animal model, gray short-tailed opossums, to test the effectiveness of sunscreen against UV-induced melanoma.
A study found that selumetinib improved cancer progression-free survival time and tumor response rate in patients with advanced uveal melanoma, but had no impact on overall survival. Treatment-related adverse events were common, affecting nearly all patients.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
The Myriad myPath Melanoma test accurately differentiates malignant melanoma from benign skin lesions with a sensitivity of 90% and specificity of 91%. This improves the standard of care for patients with melanoma, enabling healthcare providers to deliver more objective and confident diagnoses.
A study by Mayo Clinic researchers found that the size of tumors before treatment is a strong predictor of response to immunotherapy drug MK-3475. The findings suggest that decreasing baseline tumor size through surgery or other means may be more effective in inducing long-lasting remissions.